Services on Demand
Jornal de Pediatria
Print version ISSN 0021-7557On-line version ISSN 1678-4782
RIZZO, Maria Cândida V. and SOLE, Dirceu. Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy. J. Pediatr. (Rio J.) [online]. 2006, vol.82, n.5, suppl., pp.S198-S205. ISSN 0021-7557. http://dx.doi.org/10.1590/S0021-75572006000700010.
OBJECTIVE: Review the molecular mechanisms of action, efficacy, and potential side effects associated with inhaled corticosteroids (ICS) in children with persistent asthma. SOURCES: Articles in English from MEDLINE. The following terms were used: corticosteroids, inhaled corticosteroids, asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral density, and oral candidiasis. Treatment guidelines, review articles, controlled trials, meta-analyses, and systematic reviews evaluating the efficacy and the adverse events of treatment with ICS were selected. SUMMARY OF THE FINDINGS: In vivo and in vitro studies show that the available ICS have different pharmacokinetic and pharmacodynamic properties that result in different action potentials. ICS also differ as to the systemic and local side effects. The bioavailability of these products is essential in order to determine the incidence of side effects. In general, ICS are capable of controlling asthma, reducing the number of exacerbations, medical consultations, hospitalizations, and the need of oral corticosteroid (applications) bursts. Improvement can also be seen in pulmonary function, especially in patients with recent onset asthma. The most documented adverse effect is transitory decrease of growth rate. CONCLUSIONS: ICS are the main anti-inflammatory agent used to treat persistent asthma. When administered in low doses, they seem to be safe and effective. Patient monitoring allows for early detection of possible side effects associated with ICS.
Keywords : Children; asthma; inhaled corticosteroids; budesonide; beclomethasone; fluticasone; ciclesonide.